WO2016115188A1 - 5-methoxytryptophan and its derivatives and uses thereof - Google Patents
5-methoxytryptophan and its derivatives and uses thereof Download PDFInfo
- Publication number
- WO2016115188A1 WO2016115188A1 PCT/US2016/013131 US2016013131W WO2016115188A1 WO 2016115188 A1 WO2016115188 A1 WO 2016115188A1 US 2016013131 W US2016013131 W US 2016013131W WO 2016115188 A1 WO2016115188 A1 WO 2016115188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- mtp
- cycloalkyl
- alkenyl
- lps
- Prior art date
Links
- KVNPSKDDJARYKK-JTQLQIEISA-N 5-methoxytryptophan Chemical compound COC1=CC=C2NC=C(C[C@H](N)C(O)=O)C2=C1 KVNPSKDDJARYKK-JTQLQIEISA-N 0.000 title abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- -1 aiyl Chemical group 0.000 claims description 15
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 14
- 206010040047 Sepsis Diseases 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 75
- 210000004027 cell Anatomy 0.000 description 59
- 230000000694 effects Effects 0.000 description 43
- 210000004072 lung Anatomy 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 210000003024 peritoneal macrophage Anatomy 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 208000029078 coronary artery disease Diseases 0.000 description 16
- 230000009885 systemic effect Effects 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 102000004889 Interleukin-6 Human genes 0.000 description 15
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 230000000770 proinflammatory effect Effects 0.000 description 13
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 11
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 11
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 10
- 108090000397 Caspase 3 Proteins 0.000 description 10
- 101710155878 Histone acetyltransferase p300 Proteins 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 102000013918 Apolipoproteins E Human genes 0.000 description 9
- 108010025628 Apolipoproteins E Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000003896 Myeloperoxidases Human genes 0.000 description 8
- 108090000235 Myeloperoxidases Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000017306 interleukin-6 production Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 208000037487 Endotoxemia Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000034827 Neointima Diseases 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 208000005475 Vascular calcification Diseases 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000006372 lipid accumulation Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940097276 5-methoxytryptamine Drugs 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 5
- YMFNPBSZFWXMAD-UHFFFAOYSA-N JSH-23 Chemical compound NC1=CC(C)=CC=C1NCCCC1=CC=CC=C1 YMFNPBSZFWXMAD-UHFFFAOYSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 229940111134 coxibs Drugs 0.000 description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000008692 neointimal formation Effects 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000004434 Calcinosis Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002308 calcification Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 231100000516 lung damage Toxicity 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000010232 migration assay Methods 0.000 description 4
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 description 3
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 3
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 description 3
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 3
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 0 CC(C(*)CC1c2cc([O+]*)cc*2*(*)=C1)=* Chemical compound CC(C(*)CC1c2cc([O+]*)cc*2*(*)=C1)=* 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 101100182723 Mus musculus Ly6g gene Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000009527 Refractory anemia Diseases 0.000 description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- GSFCHZFQUZWTKN-UHFFFAOYSA-N 3-(5-methoxy-1h-indol-2-yl)propanoic acid Chemical group COC1=CC=C2NC(CCC(O)=O)=CC2=C1 GSFCHZFQUZWTKN-UHFFFAOYSA-N 0.000 description 1
- ZLSZCJIWILJKMR-UHFFFAOYSA-N 3-(5-methoxy-1h-indol-3-yl)propanoic acid Chemical group COC1=CC=C2NC=C(CCC(O)=O)C2=C1 ZLSZCJIWILJKMR-UHFFFAOYSA-N 0.000 description 1
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 description 1
- 108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004467 aryl imino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000007806 cell migration and invasion assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000006694 transcriptional co-activation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to 5-methoxytryptophan and its derivatives and uses thereof More specifically, the present, invention relates to novel 5-methoxytryptophan and its derivatives and uses thereof for treating inflammatory-related diseases and cancers.
- TLRs Toll-like receptors
- TLR4 can also be activated by endogenous molecules such as high mobility group box 1 (HMGB1) as a late mediator of lethal sepsis, which in turn initiates a secondary immunostimulatory cascade.
- HMGB1 high mobility group box 1
- Systemic inflammatory response syndrome is induced most commonly by systemic infection of gram-negative bacteria and the subsequent release of LPS, which activates TLR4 signaling.
- the excessive stimulation of the host immune system by LPS results in high levels of inflammatory cytokines in the circulation and disseminated intravascular coagulation.
- Systemic inflammation is characterized by metabolic syndrome, cardiovascular decompensation, multiple organ failure, disseminated intravascular coagulation and shock. These clinical manifestations are attributed to inappropriate or extensive inflammatory responses to uncontained bacterial infection and the endotoxins produced by gram-negative bacteria notably lipopolysaeeharide (LPS). Excessive immune responses lead to production of very high levels of proinflammatory cytokines (cytokine storm) and overexpression of proinflammatory mediators such as cyclooxygenese-2 (COX-2) and inducible nitric oxide synthase (iNOS). Treatment of systemic inflammatory response syndrome is limited to fluid administration, oxygen supplement, antibiotics and other supportive measures. Specific therapeutic approaches targeting proinflammatory cytokines, coagulation cascade, LPS or immune responses are unsuccessful or have marginal efficacy.
- Atherosclerosis Abnormal activation of the innate immune system and the resulting chronic inflammation have been implicated in the development and progression of chronic and metabolic diseases including atherosclerosis (Haiisson GK & Hermans son A. The immune system in atherosclerosis. Nat Immunol 12:204-212 (2011)).
- infectious agents could contribute to cardiovascular diseases.
- Vascular injury are often caused by uncontrolled infection with releases of endotoxins notably LPS.
- LPS activates toll-like receptor 4 (TLR4) which transmits signals to activate NF- B and C EBP resulting in excessive production of proinflammatory mediators thereby inducing endothelial and vascular damages.
- TLR4 toll-like receptor 4
- TLR4 can also be activated by endogenous molecules such as high mobility group box 1 (HMGBl) as a late mediator of inflammation, which contiibutes to the development of atherosclerosis.
- HMGBl high mobility group box 1
- ApoE-knockout mouse challenged with Porphyromonas gingivalis not only accelerates atherosclerosis but also increases expression of TLR2 and TLR4.
- Vascular disease is recognized as an mfiaiiimatory disease— inflammation activates endothelium and the underlying medial VSMCs (Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685-95 (2005)).
- VSMC migration and proliferation are somewhat similar to that of systemic inflammation as well as cancer cell growth and invasion.
- thai 5-MTP might protect against vascular injury-induced inflammation and the subsequent endothelial dysfunction and VSMC proliferation and migration, and consequent neointima. formation.
- This invention is based on the discovery that certain 5-methoxytryptophan and its derivatives can be used as anti- inflammatory diseases and anti-cancer agents.
- the object of the present invention is to provide 5-methoxytryptophan and its derivatives and methods for treating an inflamiiiatory-related disease and cancers with the same.
- One aspect of the present invention is related to a compound of formula (I):
- Rj is H, halogen atom, Ci-C 10 alkyl, C 2 -Ci 0 alkenyl, C 2 -Cio alkynyl, C 3 -C 2 Q cycloalkyl, or C 3 -C 20 cycloalkenyl;
- R 2 is C 1 -C 1 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -C I0 alkynyl, C 3 -C 20 cyeloalkyl, or C 3 -C 2 Q cycloalkenyl;
- R 3 is H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C
- R is H, Ci-C 10 alkyl, C 2 -C 10 alkenyl, C 2 -Cio alky
- each Rj and R 2 independently, is H or Ci-C 10 alkyl.
- j is H
- R 2 is 0 3 -0 3 alkyl.
- R 3 is H, -.-C - , alkyl, and R is H, ⁇ ⁇ - ⁇ 10 alkyl, C(0)R a , or 0(O)OR a , in which R a is H, or Cj-Ci 0 alkyl.
- R 3 is H
- R4 is H or C(0)R a , in which a is Ci-C 3 alkyl.
- Anther subset of the just-described compounds includes 5-methoxytryptophan and its derivatives, in which R 5 is H or Ci-C 10 alkyi. In these compounds, preferably, R 5 is H or C 1 -C3 alkyl.
- a further subset of the just-described compounds includes 5-methoxytryptophan and its derivatives, in which n is 1 or 2.
- alkyl refers to a saturated, linear or branched hydrocarbon moiety, such as -CH 3 or -CH(CH 3 ) 2 .
- alkyl include, but are not limited to, methyl, ethyl, w -propyl, /-propyl, n -butyl, /-butyl, and i-butyl.
- alkenyl include, but are not limited to, ethenyl, propenyl, propenylene, ally!, and 1 ,4-hutadienyi.
- alkynyi'' refers to a linear or branched hydrocarbon moiety that contains at least one triple bond, such as -C ⁇ C-CH 3 .
- alkynyi include, but are not limited to, ethynyL ethynylene, l-propynyl, 1- and 2-butynyl, and 1 -methyl-2-butynyl.
- cycloalkyl refers to a saturated, cyclic hydrocarbon moiety.
- cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyeloheptyl, and cyclooctyl.
- cycloalkenyl refers to a non-aromatic, cyclic hydrocarbon moiety that contains at least one double bond, such as cyclohexenyl.
- heterocycloalkyl refers to a saturated, cyclic moiety having at least one ring heteroatom (e.g., N, O, or S).
- heterocycloalkyl groups include, but are not limited to, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, and teti ⁇ ydrofuranyl.
- aryl refers to a hydrocarbon moiety having one or more aromatic rings. Examples of aryl moieties include phenyl (Ph), phenylene, naphthyl, naphthylene, pyrenyL anthryl, and phenanthryL
- heteroaryl refers to a moiety having one or more aromatic rings that contain at least one heteroatom (e.g., N, O, or S).
- heteroaryl moieties include fury], fiirylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl, quinazoliiiyL quinolyl, isoquinolyl and indolyl.
- halogen atom refers to F, CI, Br or I.
- Alkyl, alkenyl, alkynyl, cvcioalkyl, cycloalkenyl, heterocycloalkyi, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise.
- Possible substituents on cvcioalkyl, cycloalkenyl, heterocycloalkyi, aryl, and heteroaryl include, but are not limited to, Ci-C 10 alkyl, C 2 -C u > alkenyl, C 2 -Cio alkynyl, C 3 -C 2 Q cycloalkyi, C 3 -C 2 o cycloalkenyl, C C 2 o heterocycloalkyi, C I -C 2 Q heterocycloalkenyl, Ci-Cio alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, Ci-C 10 alkylamino, C C 20 dialkylamino, arylamino, diaiylamino, Ci-Cio alkykulfonamino, arylsulfonamino, Ci-C 10 alkylimino, arylimino, Ci-Cio alkylsulfonimin
- alkyl, alkenyl, or alkynyl include all of the above -recited substituents except Ci-C 10 alkyl.
- Cycloalkyi, cycloalkenyl, heterocycloalkyi, heterocycloalkenyl, aryl, and heteroaryl can also be fused with each other.
- a salt for example, can be formed between an anion and a positively charged group (e.g., amino) on 5-methoxytryptophan and its derivatives.
- Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, triiluoroaeetate, acetate, maiate, tosylate, tartrate, fumurate. glutamate, glucuronate. lactate, glutarate, and maleate.
- a salt can also be formed between a cation and a negatively charged group (e.g., earhoxylate) on 5-methoxytryptophan and its derivatives.
- Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
- the compounds also include those salts containing quaternary nitrogen atoms.
- prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds as described above.
- a solvate refers to a complex formed between an active 5 -metlioxy tryptophan or its derivative and a pharmaceutically acceptable solvent.
- pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.
- One subset of the just-described compounds includes 5-methoxytryptophan derivatives, with the proviso that j, R 3 , 3 ⁇ 4 and R 5 are not H when R 2 is Ci-C 10 alkyL
- this invention features a method for treating an inflammatory-related disease.
- the method includes administering to a subject in need thereof and effective amount of one or more compounds of formula (I) shown above.
- inflammatory -related diseases include sepsis.
- Systemic Lupus Erythematosus (SLE) cardiovascular diseases, metabolic syndrome, cancer, septicemia and diverse inflammatory joint, gastrointestinal, and renal diseases.
- this invention also features a method for treating a cancer.
- the method includes administering to a subject in need thereof and effective amount of one or more compounds of formula (I) shown above.
- Cancer that can be treated by the method of this invention includes both solid and haexnatological tumours of various organs.
- solid rumors include pancreatic cancer, bladder cancer (e.g., urothelium cancer), colorectal cancer, breast cancer (e.g., metastatic breast cancer), male genital tract cancer (e.g., seminal vesicle cancer, testes cancer, germ cell tumors, and prostate cancer such as androgen-dependeiit and androgen- independent prostate cancer), renal cancer (e.g., metastatic renal cell carcinoma), hepatocellular cancer, lung cance (e.g., small cell lung cancer, non-small cell lung cancer, bronchioloalveoiar carcinoma, and adenocarcinoma of the lung), ovarian cancer (e.g., progressive epithelial or primary peritoneal cancer), cervical cancer, uterus cancer, gestational trophoblastic disease (e.g., choriocarcinoma), gastric cancer, bile duct cancer, gallbladder cancer, small intestine cancer, esophageal cancer, oropharynge
- Schwannoma meningioma, neuroblastoma, and neuroma
- head and neck cancer e.g., squamous cell carcinoma of the head and neck
- melanoma plasmacytoma
- endocrine gland neoplasm e.g., pituitary adenoma, thyroid cancer, and adrenal tumor
- neuroendocrine cancer e.g., metastatic neuroendocrine tumors
- brain tumors e.g., glioma, anaplastic oligodendroglioma, glioblastoma multiforme, and astrocytoma such as adult anaplastic astrocytoma
- bone cancer e.g., Kaposi's sarcoma.
- hematologic malignancy examples include acute myeloid leukemia, chloroma, chronic myelogenous leukemia or CML f e.g., accelerated CML s and CML blast phase), acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkm's disease, non-Hodgkin's lymphoma (e.g., follicular lymphoma, cutaneous T-cell lymphoma such as mycosis fungoides, and mantle cell lymphoma), B-cell lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes (e.g., refractory anemia, refractory anemia with ringed siderblasts, refractory anemia with excess blasts or RAEB, and RAEB in transformation or RAEB-T, and myeloproliferative syndromes).
- acute myeloid leukemia chloroma,
- treating or refers to administering one or more 5-methoxytryptophan and its derivatives to a subject, who has an above-described disease, a symptom of such a disease, or a predisposition toward such a disease, with the purpose to confer a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the above-described disease, the symptom of it, or the predisposition toward it.
- an effective amount refers to the amount of a
- 5-methoxytryptophan or its derivative that is required to confer a therapeutic effect on the treated subject.
- Effective amounts may vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other agents.
- compositions containing one or more 5-methoxytryptophan and its derivatives described above for use in treating one of the above-described diseases and cancers, and the use of such a composition for the manufacture of a medicament for this treatment.
- 5-MTP 5-MTPE > or NACT-5-MTP wherein 5-MTP refers to 5-methoxytryptophan; 5-MTPE refers to ester-5-MTP; and NACT-5MTP refers to N-acetyI-5-MT
- FIG. 1 A shows structures of 5-MTP and its derivatives of the present invention.
- FiG. IB shows thin layer chromatography and mass spectra of
- FIGs. 1C-1E show H MR spectra of 5-MTP and its derivatives (5-MTPE and NACT-5MTP).
- FiG. IF shows results of suppressive activity of 5-MTP and its derivatives in PMA-induced A549 COX-2 expression.
- FIG. 2A shows results of cell migration assays in A549 lung cancer cells by treating 5-MTP or 5-MTPE.
- FIG 2B shows results of cell migration assays in BT474 and T47D breast cancer cells by treating 5-MTPE.
- FIG 2C shows results of tumor xenograft experiment by treating 5-MTP or 5-MTPE, wherein * denotes p ⁇ 0.05, and ** donates p ⁇ 0.01.
- FIGs. 3A-3F respectively show inhibitions of 5-MTP on LPS-indiiced expression of COX -2 and different cytokines.
- FIGs. 4A-4B shows effect of 5-MTPE on cell viability and IL-6 production.
- FIG 5 A shows survival of mice injected with and without 5-MTP or 5-MTPE before these animals were challenged with LPS.
- FIG 5B shows survival of mice injected with and without 5-MTP 30 mins after cecal ligation and puncture (CLP) surgery.
- FIG 5C shows inhibitions of 5-MTP on mice challenged with LPS.
- FiG 5D shows results of bronchoalveolar lavage fluid (BALF).
- FIGs. 6A-6B show inhibitions of 5-MTP on LPS-induced expression ofCOX-2 and iNOS.
- FIGs. 7A-7D respectively show different proinflammatory cytokines levels in mice treated with or without 5-MTP.
- FiG. 7E shows proinflammatory cytokines levels in peritoneal macrophages treated with or without 5-MTP.
- FiG. 7F shows serum 5-MTP levels in mice treated with saline or LPS with or without 5-MTP.
- FiG. 8A shows inhibitions of 5-MTP on neutrophil infiltration.
- FiG. 8B shows MPO activity in lung tissues of mice treated with saline or LPS with or without 5-MTP.
- FiG. 8C shows serum chemokine levels in mice treated with saline or LPS with or without 5-MTP.
- FIG 9A shows activated caspase-3 level in lung tissues of mice treated with saline or LPS with or without 5-MTP.
- FIG. 9B shows activated caspase-3 level in splenocytes of mice treated with saline or LPS with or without 5-MTP.
- FIG 9C show ; s spleen weight/body weight ratio of LPS induced-mice treated with or without 5-MTP.
- FIG 1 OA shows irnmunob!otted results ofp38.
- phospho-p38 p-p38
- ERK1/2 ERK1/2
- phospho-ERKl/2 p-ERKl/2
- ⁇ -actm m RAW264.7 cells treated with or without 5-MTP.
- FIG 10B shows F-t B promoter activity in RAW264.7 cells treated with or without 5-MTP.
- FIG IOC shows immunoblotted results of NF- ⁇ p65, phospho-NF- ⁇ p65 (p-p65) (Ser536) or ⁇ -actin in RAW264.7 cells treated with or without 5-MTP.
- FIG. 10D shows phosphor-p65 level in the lysates of peritoneal macrophages treated with LPS with or without 5-MTP.
- FIG I0E show ; s phosphor-p65 level in lung tissues of mice after LPS infusion with or without 5-MTP.
- FIG 10F shows p300 FLAT activity in peritoneal macrophages treated with LPS in the presence or absence of 5-MTP.
- FIG 10G shows p300 HAT activity in lung tissues of mice after LPS infusion with or without 5 -MTP.
- FIG. 10H shows schematic illustration of the signaling mechanisms via which 5-MTP inhibits systemic inflammatory syndrome.
- FIGs. ⁇ 1 ⁇ - ⁇ 1 ⁇ shows IL-6 levels in culture supernatants of RAW264.7 cells treated with 5-MTP, 5-MTPE, COX-2 inhibitors (NSC398 or SC560) and NF- ⁇ inhibitor JSH-23 after LPS treatment.
- FIG I IC shows luciferase activity after AW264.7 cells were transfeeted with COX-2 promoter-luciferase plasmid.
- FIG 12B shows inhibition of 5-MTP on lipid accumulation and atherosclerotic lesion formation in arteries of ApoE-deficient mice treat with high fat diet.
- FIG 12C shows inhibitions of 5-MTPE on lipid accumulation in atherosclerotic lesions of ApoE-deficient mice treat with high fat diet.
- FIG. 12D shows suppressive effects of 5-MTP and 5-MTPE on calcifying medium-induced calcification in vascular smooth muscle cells.
- FIG. 12E shows inhibitions of 5-MTP on high fat diet-induced vascular calcification in ApoE-deficient mice.
- Mouse RAW264.7 macrophages were from the American Type Culture Collection and cultured in DMEM containing 10% FBS. Cells were typically pre- incubated with or without 5-MTP (Sigma- Aldrich) for 30 mi before LPS treatment, unless specified otherwise. The duration of LPS (100 ttg/iiil) treatment varied depending on the experiment.
- peritoneal macrophage isolation C57BL/6J mice were injected intraperitoneally with 2 ml of 4% thioglycollate.
- the peritoneal cavity was washed with 5 ml of ice-cold RPMI1640 medium, and cells from the peritoneal exudates were collected by centiifugation, and suspended in RPMII640 medium, then seeded on 15 -cm dishes and allowed to adhere for 4 h. Floating cells were washed out, and adherent cells were used as peritoneal macrophages in the experiments.
- the cells were incubated with or without LPS (100 ng ml) for the indicated time before each experiment, as in the protocol for the RAW264.7 cells.
- cells (10 /well) were seeded on the upper chamber (6.5 -mm insert, 8- ⁇ polycarbonate membrane; Corning Inc.), which was placed in each well of a 24-well plate.
- the lower chamber was filled with 700 uL DMEM supplemented with 10% FBS.
- cells were seeded onto the upper chamber insert coated with Matrigel (BD Biosciences) under the same conditions as the transwell migration assays. At the indicated time, no mi grated cells that remained at the top surface of the insert were removed with a cotton swab.
- mice Six- week -old male CB-17 SCID mice, purchased from BioLASCO, were housed in a daily cycle of 12-h light and 12-h darkness and pathogen-free conditions at 26°C at the Animal Center of the National Health Research Institutes.
- A549-luc-C8 cells (Caliper Life Sciences), cultured in RPMI- 1640 supplemented with 10% FBS, were pretreated with 100 ⁇ . ⁇ 5-MTP, 100 ⁇ 5-MTPE or vehicle for 5 h and were inoculated into the flank of mice subcutaneously (s.c.) (5 x 10 6 cel!s/mouse).
- the size of s.c. tumors were caliper-measured twice weekly.
- the tumor volume was calculated according to the formula of length x width x width/2.
- the tumor growth was also monitored weekly by an IVIS spectrum imaging system. Mice were euthanized at day 52. Subcutaneous tumors and lungs were removed and fixed with 10% Formalin. Nodules on each lobe of the lungs were counted.
- mice C57BL/6 mice (6-8 wks old) were treated intraperitoneally with saline or with different concentrations of 5-MTP (23.4 or 100 mg/kg) for 30 min before intraperitoneal administration of LPS (60 mg/kg). Animals were monitored for survival and other clinical signs including ruffled fur, lethargy, diarrhea, and body weight loss. Some animals were sacrificed at different times after LPS injection. Blood samples, peritoneal exudates. kings, and spleens were collected. All mouse experiments were approved by the Institutional Animal Care and Use Committee, National Health Research Institutes.
- Cytokine levels in the culture supematants and serum were determined in microtiter plates (90-well) by a specific sandwich ELISA (Biosource) as previously described (Wu, J.Y. & Kuo, C.C. Pivotal role of ADP-rihosylation factor 6 in Toll-like receptor 9-mediated immune signaling. J ⁇ Chem 287, 4323-4334 (2012)) (Lee, GL., et al TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production. Arierioscler Thromb Vase Biol 32. 2751-2760 (2012); hereinafter, Lee, G.L., et al). Western blot analysis
- Cellular protein were resolved by 5% to 20% SDS-PAGE and transferred to nitrocellulose membranes and blotted with specific antibodies as previously described (Lee, G.L., et al).
- RAW264.7 macrophages were cotransfected with COX-2 promote r- luc i f era se , IL-6 promoter-luciferase constructs as previously described (Lee, G.L., et al) or p xN F- ⁇ - luc ⁇ fe r ase (Stratagene) and pcDNA3.1- ⁇ -galactosidase plasniids using FuGENE 6 (Roche). After overnight transfection, the cells were incubated with or without LPS in the presence or absence of 5-MTP for S h. After treatment, cells were lysed, and luciferase activity was measured using an assay kit (Promega). ⁇ -galactosidase activity was used to normalize the data.
- MPO activity assay Myeloperoxidase (MPO) activity of lung tissue was assayed by Myeloperoxidase fluorometric detection kit (Enzo Life Sciences).
- lung tissue specimens were homogenized by Tissuelyser II (Qiagen) in tissue protein extraction buffer (pH 7.4 25 mM Tris buffer, 150 mM NaCl, 0.5% sodium deoxycholate, 2% NP-40 and 0.2% SDS), and centrifuged at 12,000 x g for 20 min at 4°C.
- the supematants were removed and the pellets were homogenized by Tissuelyser II for 30 seconds in 1 ml assay buffer with 0.5% hexadecyltrimethylammonium, and then samples were frozen, thawed three times, andceiitrimged at 8,000 x g for 20 min. Collected supematants and standard were mixed with reaction cocktail (50 ⁇ detection reagent and 20 ⁇ hydroge peroxide in IX assay buffer at room temperature in the dark. After 30 min incubation, MPO activity was determined by measuring the fluorescence intensity at excitation 530 nm and emission at 600 nm in a fluorescent plate reader.
- Caspase-3 activity was determined by the cleavage of the fluorometric substrate z-DEVD-AMC (Upstate Biotechnology) as previously described (Kuo, C.C., Liang, CM., Lai, C.Y. & Liang, S.M. Involvement of heat shock protein(Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynudeotide. J Immunol 178, 6100-6108 (2007)).
- the lungs were perfused with saline, and immersed in formalin for 24 h.
- Tissue blocks were placed in formalin, dehydrated in a graded series of ethanol, embedded in paraffin, cut into 3 ⁇ -thick serial sections, and stained with haematoxylin and eoshi for detecting inflammatory cells, alveolar congestion and alveolar septal wall thickness and interstitial edema.
- ApoE-deficient mice at 6 weeks were placed on a Western high fat diet containing 1.25% cholesterol and 21% fat (Researc Diets). The mice were simultaneously treated with vehicle (PBS), 5-MTP or 5-MTPE (23.4 mg/kg body weight, 3 times a week) by intraperitoneal injection. After 8 weeks, the aortic trees were dissected and lesions examined in the aortic arch and its branches. The aortas were carefully freed of comiective and adipose tissue under a dissection microscope, opened longitudinally and stained with Oil red O.
- ApoE-deficient mice were fed with on a Western high fat diet containing 1.25% cholesterol and 21% fat (Research Diets) starting at 6 weeks of age.
- the mice were simultaneously treated with vehicle (PBS) or 5-MTP (23.4 mg kg body weight, 3 times a week) by intraperitoneal injection.
- the aortic trees were dissected and lesions examined in the aortic arch and its branches.
- Vascular calcifications in the aortic root were evaluated by von Kossa staining.
- mice were treated with vehicle (PBS) or 100 mg/kg of 5-MTP (Sigma, M4001 ) by IP injection 3 times a week.
- 5-MTP was dissolved in 0.05 N HC1 (made in PBS) first, pH adjusted to 7.4 by NaOH, and then a stock solution of 6.5 mg/mL was prepared with PBS. The stock solution was then sterilized by filtering through a 0.22 pm-filter before use.
- mice were anesthetized with tribromoethanol solution (500-750 mg/kg), perfused with saline, followed by 10% neutral-buffered- fomralin.
- the contralateral control right common carotid artery
- ligated LCCA were then carefully dissected, excised, and immersed in 10% formalin before processing and embedding in paraffin.
- both 5-MTPE and NACT-5MTP dose -dependency blocked PMA-induced COX-2 protein expression in A549 cells. Furthermore, the COX-2 suppressive activity of both 5-MTP derivatives is potent than that of 5-MTP.
- 5-MTPE ⁇ 5-methoxytrypiophaH derivatives block cancer migration and tumor growth.
- Lung cancer A549 and breast cancers BT474 and T47D cells were pretreated w r ith different concentrations of 5-MTP or 5-MTPE for 30 min, then stimulated with PMA for 4 h or 24 h. Cell migration was measured by the transwell migration assay. The results show that 5-MTP, 5-MTPE and NACT-5MTP abrogated A549 (FIG. 2A) and breast cancer BT474 and T47D (FIG. 2B) cell migration induced by PMA for 4 h or 24 h.
- A549 (5x I0 6 cells) was injected subcutaneously into the flank of SCID-Beige mice. 10 mice each received intraperitoneal injection of 5-MTP (100 mg/kg), 5-MTPE (100 mg/kg) or vehicle twice weekly. Caliper measurement of the subcutaneous tumor volume periodically for 7 weeks. The result shown in FIG. 2C indicates that 5-MTP and 5-MTPE suppressed tumor volume in a time -dependent manner. The average tumor volume at 7-week in the 5-MTP treated group was—50% of that in the control group.
- FIGs. 2A-2C indicate the 5-MTP and its derivatives inhibit cancer migration and tumor growth in vitro and in vivo.
- 5-methoxytryptophan derivatives inhibit LPS-induced COX-2 expression and cytokine production in macrophages.
- RAW264.7 cells After pretreating mouse macrophage RAW264.7 cells with different concentrations of 5-MTP for 30 min, cells were stimulated with LPS for 8 h. Cell lysates were immunoblotted with antibodies for COX-2 or ⁇ -actin. In addition, RAW264.7 cells were trans fected with COX-2 promoter- luciferase plasmid. After 24 h transfection, the cells were incubated with LPS for 8 h. Luciferase activity was measured. The experiments were repeated 3 times with similar results. The results shown in FIGs. 3A-3B confirmed that 5-MTP blocked LPS-induced COX-2 protein expression and promoter activity in a concentration-dependent manner in RAW264.7 cells.
- peritoneal macrophages were stimulated with LPS with or without 5-MTP. After 8 h, COX-2 protein expression was determined by western blot. The experiments were repeated 3 times with similar results. The results shown in FIG. 3C indicates that 5-MTP inhibited LPS-induced COX-2 expression in primary mouse peritoneal macrophages.
- RAW264.7 cells and IL-6 promoter-luciferase plasmid transiected RA 264.7 cells were pretreated with different concentrations of 5-MTP for 30 iiiin, followed by LPS stimulation for 8 h.
- IL-6 promoter activity was measured by luciferase assay.
- IL-6 level in culture supernatants was measured by ELISA.
- 5-MTP inhibited LPS-induced IL-6 promoter activity and protein expression in RAW264.7 cells in a concentration-dependent manner, comparable to its inhibition of COX-2 expression (FIGs. 3A-3B).
- peritoneal macrophages were stimulated with LPS with or without 5-MTP. After 24 h, proinflammatory cytokines were measured by ELISA. The results shown in FIG. 3F indicates that 5-MTP mhibited IL-6, IL- ip and TNF-a production in peritoneal macrophages and TNF- production in RAW264.7 cells (data not shown).
- RAW264.7 cells were treated with different concentrations of 5-MTP or 5-MTPE for 24 h. Cell viability was determined by MTT assay.
- cells were stimulated with LPS for 24 h. IL-6 level in culture supernatants was measured by ELISA. As shown in FIGs. 4A-4B, the 5-MTP derivatives, 5-MTPE significantly inhibited LPS-induced cytokine production but not cell viability.
- 5-methoxytryptophan derivatives protect against lethal endotoxemia in mice.
- mice treated with LPS started to die at day 1 , and more than 65% of mice died at 72 h.
- none of the mice treated with 5-MTP died at day 1 and only 20% of endotoxemic mice died at day 3 while no mortality was observed in control groups (saline or 5-MTP alone).
- 5-MTPE showed a 100% protective capacity in LPS-induced lethal endotoxemia.
- CLP cecal ligation and puncture
- paraffin-embedded sections were prepared from lungs of mice injected with 60 mg/kg LPS with or without saline or 5-MTP for the indicated time. Lung tissues were stained with hematoxylin and eosin and examined under light microscopy. The results are shown in FIG. 5B, in which scale bars represent 100 ,um.
- bronchoalveolar lavage fluid was isolated from mice treated with LPS with or without various concentrations of 5-MTP for 24 h. Cell number in BALF was determined by trypan blue exclusion assay.
- BALF bronchoalveolar lavage fluid
- paraffin-embedded sections were prepared from lungs of mice injected with 60 mg/kg LPS with or without saline or 5-MTP at 12 h, 16 h and 24 h.
- COX-2 and inducible nitric oxide synthase (iNOS) protein levels in lung tissues were determined by immimohistochemistry by staining with anti-COX-2 and anti-iNOS antibodies, respective ly.
- FIGs. 6A-6B in which scale bars represent 100 ⁇ .
- 5-MTP suppresses COX-2 (FIG.
- FIG 6A lung tissues of LPS-iiiduced eiidotoxemia, which is consistent with the results that 5-MTP suppresses macrophage COX-2 expression and cytokine productions (especially, iNOS productions).
- mice were injected mtraperitoneally with or without different concentrations of 5-MTP or saline for 30 mm, followed by LPS administration for the indicated time.
- the result shown hi FIGs. 7A-7D respectively indicates that 5-MTP abated the elevation of blood level of IL- ⁇ , TNF-a, IL-6 and INF- in LPS-treated mice in a dose- and time -dependent manner.
- 5-MTP at 23.4 mg/kg significantly reduced all the tested cytokines and at 100 mg/kg it reduced the cytokines to the basal level.
- 5-MTP suppressed the rise of 11.- 12 in LPS-treated mice (data not shown).
- Ave evaluated the effect of 5-MTP on IL- ⁇ and IL-6 production ex vivo in peritoneal macrophages isolated from untreated or 5-MTP -treated endotoxemic mice.
- ELiSA proinflammatory cytokines
- mice Thirty min after saline or 5-MTP administration, mice were injected iiitraperitoneally with LPS at 4 h, 12 h, 16 h and 24 h. Paraffin-embedded lung tissue specimens were subjected to immmiohistochemical LyoG staining for determination of neutrophil infiltration in lung tissues. The results are shown in FIG. 8A, in which scale bars represent 100 ⁇ . As shown in FIG. 8 A, neutrophil infiltration was slightly increased at 4 h and became markedly increased at 12 h and thereafter following LPS treatment. Also, 5-MTP dose-dependent ly reduced neutrophil infiltration; and at 100 mg/kg, it reduced the infiltration almost to the basal level.
- the results shown in FIG. 8C indicate that LPS-induced elevation of chemokines, CXCL1, MCP- L RANTES and eotaxin in the serum was blunted by 5-MTP treatment at 24 h.
- 5-MTP prevents LPS-induced lung and spleen cell apoptosis.
- Paraffin-embedded sections were prepared from lung tissues of mice treated with saline or LPS (60 mg kg) with or without various concentrations of 5-MTP for 12 or 16 h.
- Activated easpase-3 level in lung tissues was determined by immunohistochemical staining of cleaved caspase-3.
- FIG. 9A in which scale bars represent 200 ⁇ .
- LPS treatment resulted in a significant increase in apoptosis as demonstrated by increased cleaved caspase-3 at 12 and 16 h which was reduced by 5-MTP.
- caspase-3 activity in splenoeytes of mice treated with saline, LPS or LPS plus 5-MTP (100 mg/kg) for 16 h was measured by fluorogenic substrate as described above.
- 5-MTP also prevented LPS-induced caspase-3 cleavage in spleen cells.
- SW BW spleen weight/body weight
- 5-MTP suppresses p300 histone acety .transferase (HAT) activation.
- Activation of p300 HAT plays an important role in transcriptional coactivation of NF-t B and expression of inflammatory genes, such as COX-2 and iNOS.
- NF-t B transcriptional coactivation of NF-t B
- inflammatory genes such as COX-2 and iNOS.
- p300 HAT activity in peritoneal macrophages treated with LPS in the presence or absence of 5-MTP (50 uM) for the indicated time was measured with an p300 HAT activity assay kit.
- LPS activated p300 HAT in peritoneal macrophages at 4 h and persisted for 24 h.
- 5-MTP significantly blocked p300 HAT activation up to 24 h.
- FIG. 10G in vivo, LPS elevated p300 HAT activity in lung tissues but was suppressed by 5-MTP as in macrophages in vitro.
- COX-2 inhibitors are considered to be anti- inflammatory agent.
- RAW264.7 cells after pretreating RAW264.7 cells with different concentrations of 5-MTP, 5-MTPE, COX-2 inhibitors (NSC398 or SC560) and NF- ⁇ inhibitor JSH-23 for 30 min, cells were stimulated with LPS.
- RAW264.7 cells were also transfected with COX-2 promoter-luciferase plasmid. After 24 h trans fection, the cells were incubated with LPS for 8 h. Luciferase activity was measured.
- FIG. 11A shows IL-6 level in culture supematanis measured by ELISA at 24 h after LPS treatment. The results indicate that all used agents dose-dependably blocked LPS-induced IL-6 production in RAW264.7 cells. In comparison between each other, 5-MTPE possesses a better suppressive capacity on IL-6 production.
- 5-MTP inhibited LPS-induced systemic inflammation via suppressing NF- ⁇ activation.
- F-KB inhibitor has been reported to be anti-inflammatory and anti-cancer agent.
- JSH-23 effect both 5-MTP and 5MTPE dose-dependently blocked LPS-induced COX-2 and IL-6 production in RAW264.7 cells.
- the COX-2 and IL-6 suppressive activity of 5-MTPE is potent than that of NF- ⁇ inhibitor JSH-23, as shown in FIG. llB-1 1C.
- Serum 5-MTP concentrations inversely correlate with coronary artery disease
- 5-MTP derivatives protects against atherosclerosis and vascular calcification in ApoE-deficient mice
- vascular smooth muscle cell (VSMC) calcification is the major phenomenon to induce atherosclerotic vascular calcification in cardiovascular disease (CVD).
- CVD cardiovascular disease
- 5-MTP derivatives Calcifying medium-induced calcification in vascular smooth muscle cells was reduced by 5-MTP and 5-MTPE (FIG. 12D).
- 5-MTP also prevented high fat diet-induced vascular calcification in ApoE-deficient mice (FIG. 12E).
- 5-MTP reduces neointima formation in a mouse carotid artery ligation model
- 5-MTP and its derivatives are efficacious in controlling COX-2, cytokine and inflammatory mediator overproduction, accompanied by prevention of cancer cell growth and migration, lung damages and improvement of mortality caused by systemic inflammation.
- 5-MTP may exert its effects by functioning as a circulating hormone to control excessive COX-2 expression and systemic inflammation.
- 5-MTP and its derivatives will be a valuable drug and/or serves as a lead compound for developing new drugs for treating cancer and inflammatory diseases such as sepsis.
- SLE Systemic Lupus Erythematosus
- cardiovascular diseases such as sepsis.
- metabolic syndrome CAD
- cancer septicemia
- diverse inflammatory joint gastrointestinal and renal diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2973590A CA2973590C (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
CN201680005720.4A CN107847485B (en) | 2015-01-13 | 2016-01-13 | 5-methoxy tryptamine acid and its derivative and use |
NZ733731A NZ733731A (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
EP16737771.2A EP3244887A4 (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
US15/543,001 US20180009750A1 (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
AU2016206795A AU2016206795B2 (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
US16/166,416 US10577322B2 (en) | 2015-01-13 | 2018-10-22 | 5-methoxytryptophan and its derivatives and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562102675P | 2015-01-13 | 2015-01-13 | |
US62/102,675 | 2015-01-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/543,001 A-371-Of-International US20180009750A1 (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
US16/166,416 Division US10577322B2 (en) | 2015-01-13 | 2018-10-22 | 5-methoxytryptophan and its derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016115188A1 true WO2016115188A1 (en) | 2016-07-21 |
Family
ID=56406307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/013131 WO2016115188A1 (en) | 2015-01-13 | 2016-01-13 | 5-methoxytryptophan and its derivatives and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180009750A1 (en) |
EP (1) | EP3244887A4 (en) |
CN (1) | CN107847485B (en) |
AU (1) | AU2016206795B2 (en) |
CA (1) | CA2973590C (en) |
NZ (1) | NZ733731A (en) |
TW (1) | TWI588128B (en) |
WO (1) | WO2016115188A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI588128B (en) | 2015-01-13 | 2017-06-21 | 財團法人國家衛生研究院 | 5-methoxytryptophan and its derivatives and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448785A (en) * | 1978-01-09 | 1984-05-15 | Sandoz, Inc. | N-Unsaturated fatty acid amides of tryptophan ester homologues and anti-cholesteric use thereof |
US7855215B2 (en) * | 2004-09-28 | 2010-12-21 | Novartis Ag | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors |
US20120329846A1 (en) * | 2005-07-01 | 2012-12-27 | Ajinomoto Co., Inc. | Therapeutic agent for inflammatory bowel disease and tnf-alpha production inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814546A1 (en) * | 1998-04-01 | 1999-10-07 | Hoechst Marion Roussel De Gmbh | (S) -2- (Biphenyl-4-sulfonylamino) -3- (1H-indol-3-yl) propionic acid derivatives |
EP1574499A1 (en) * | 2004-03-08 | 2005-09-14 | DKFZ Deutsches Krebsforschungszentrum | Inhibitors of DNA methylation in tumor cells |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
TW201026667A (en) | 2008-09-30 | 2010-07-16 | Merz Pharma Gmbh & Co Kgaa | Glycine b antagonists |
TWI588128B (en) | 2015-01-13 | 2017-06-21 | 財團法人國家衛生研究院 | 5-methoxytryptophan and its derivatives and uses thereof |
-
2016
- 2016-01-12 TW TW105100775A patent/TWI588128B/en active
- 2016-01-13 CN CN201680005720.4A patent/CN107847485B/en active Active
- 2016-01-13 US US15/543,001 patent/US20180009750A1/en not_active Abandoned
- 2016-01-13 CA CA2973590A patent/CA2973590C/en active Active
- 2016-01-13 WO PCT/US2016/013131 patent/WO2016115188A1/en active Application Filing
- 2016-01-13 EP EP16737771.2A patent/EP3244887A4/en active Pending
- 2016-01-13 AU AU2016206795A patent/AU2016206795B2/en active Active
- 2016-01-13 NZ NZ733731A patent/NZ733731A/en unknown
-
2018
- 2018-10-22 US US16/166,416 patent/US10577322B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448785A (en) * | 1978-01-09 | 1984-05-15 | Sandoz, Inc. | N-Unsaturated fatty acid amides of tryptophan ester homologues and anti-cholesteric use thereof |
US7855215B2 (en) * | 2004-09-28 | 2010-12-21 | Novartis Ag | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors |
US20120329846A1 (en) * | 2005-07-01 | 2012-12-27 | Ajinomoto Co., Inc. | Therapeutic agent for inflammatory bowel disease and tnf-alpha production inhibitor |
Non-Patent Citations (1)
Title |
---|
CHENG ET AL.: "Quiescent and Proliferative Fibroblasts Exhibit Differential p300 HAT Activation through Control of 5-Methoxytryptophan Production.", PLOS ONE, vol. 9, no. 2, 11 February 2014 (2014-02-11), pages e88507, XP055446487, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921189/pdf/pone.0088507.pdf> [retrieved on 20160222] * |
Also Published As
Publication number | Publication date |
---|---|
AU2016206795A1 (en) | 2017-08-17 |
US10577322B2 (en) | 2020-03-03 |
EP3244887A4 (en) | 2018-06-13 |
AU2016206795B2 (en) | 2020-09-24 |
TWI588128B (en) | 2017-06-21 |
TW201625526A (en) | 2016-07-16 |
CA2973590C (en) | 2024-06-04 |
CA2973590A1 (en) | 2016-07-21 |
CN107847485B (en) | 2023-11-10 |
US20180009750A1 (en) | 2018-01-11 |
US20190092725A1 (en) | 2019-03-28 |
NZ733731A (en) | 2022-09-30 |
CN107847485A (en) | 2018-03-27 |
EP3244887A1 (en) | 2017-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Cicco et al. | ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo | |
Li Chew et al. | In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K–AKT signaling at endosomes | |
Schoner et al. | Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth | |
US11712443B2 (en) | 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors | |
WO2020191227A1 (en) | Methods for controlling prostaglandin-mediated biological processes | |
US11278549B2 (en) | Method of treating obesity | |
AU2005257982B8 (en) | Carbazole formulations for the treatment of psoriasis and angiogenesis | |
JP2018514557A (en) | Methods for treating cancer using STAT3 pathway inhibitors and kinase inhibitors | |
JP2015214579A (en) | Cancer cell apoptosis | |
KR102382771B1 (en) | Combination Therapy for Proliferative Diseases | |
US10577322B2 (en) | 5-methoxytryptophan and its derivatives and uses thereof | |
KR102410362B1 (en) | Combination Therapy for Proliferative Diseases | |
WO2011011984A1 (en) | Sterol derivatives and their synthesis and use | |
CN114599638B (en) | Small molecule liver X receptor modulators and uses thereof | |
Li et al. | Engelharquinone suppresses lipopolysaccharide-induced inflammation and proliferation of human liver cancer SMCC7721 cells via inhibition of NF-κB and MAPK signaling pathway | |
WO2022028429A1 (en) | Novel copi/arf1-lipolysis pathway inhibitor and compound for eradicating cancer stem cells and inducing damp-mediated anti-tumor immune response | |
Ain et al. | Metabolic changes and their characterization | |
KR102404681B1 (en) | Pharmaceutical composition comprising 2,4,6-trihydroxyacetophenone as a active ingredient for treating prostate cancer | |
KR20220060033A (en) | Pharmaceutical Composition for Preventing or Treating Cancer Comprising NVS-CECR2-1 | |
CA3151738A1 (en) | Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof | |
WO2014028079A1 (en) | Treatment of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16737771 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2973590 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2016737771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201680005720.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016206795 Country of ref document: AU Date of ref document: 20160113 Kind code of ref document: A |